These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 8584284)

  • 1. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease.
    Allain P; Le Bouil A; Cordillet E; Le Quay L; Bagheri H; Montastruc JL
    Neurotoxicology; 1995; 16(3):527-9. PubMed ID: 8584284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
    Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
    Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma sulfate concentration and hyperhomocysteinemia in hemodialysis patients.
    Brunetti M; Terracina L; Timio M; Saronio P; Capodicasa E
    J Nephrol; 2001; 14(1):27-31. PubMed ID: 11281340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cysteine elevation in levodopa-treated patients with Parkinson's disease.
    Müller T; Kuhn W
    Mov Disord; 2009 Apr; 24(6):929-32. PubMed ID: 19243072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
    Müller T; Kuhn W
    Mov Disord; 2009 Jul; 24(9):1339-43. PubMed ID: 19425084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma homocysteine levels and Parkinson disease: disease progression, carotid intima-media thickness and neuropsychiatric complications.
    Hassin-Baer S; Cohen O; Vakil E; Sela BA; Nitsan Z; Schwartz R; Chapman J; Tanne D
    Clin Neuropharmacol; 2006; 29(6):305-11. PubMed ID: 17095893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy.
    Todorović Z; Dzoljić E; Novaković I; Mirković D; Stojanović R; Nesić Z; Krajinović M; Prostran M; Kostić V
    J Neurol Sci; 2006 Oct; 248(1-2):56-61. PubMed ID: 16774768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
    Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M
    Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
    Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
    Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma homocysteine and cysteine levels in retinal vein occlusion.
    Pinna A; Carru C; Zinellu A; Dore S; Deiana L; Carta F
    Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):4067-71. PubMed ID: 16936125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated plasma levels of homocysteine in Parkinson's disease.
    Kuhn W; Roebroek R; Blom H; van Oppenraaij D; Przuntek H; Kretschmer A; Büttner T; Woitalla D; Müller T
    Eur Neurol; 1998 Nov; 40(4):225-7. PubMed ID: 9813406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine and cognitive impairment in Parkinson's disease: a biochemical, neuroimaging, and genetic study.
    Rodriguez-Oroz MC; Lage PM; Sanchez-Mut J; Lamet I; Pagonabarraga J; Toledo JB; García-Garcia D; Clavero P; Samaranch L; Irurzun C; Matsubara JM; Irigoien J; Bescos E; Kulisevsky J; Pérez-Tur J; Obeso JA
    Mov Disord; 2009 Jul; 24(10):1437-44. PubMed ID: 19452554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy.
    Bouhaddi M; Vuillier F; Fortrat JO; Cappelle S; Henriet MT; Rumbach L; Regnard J
    Auton Neurosci; 2004 Nov; 116(1-2):30-8. PubMed ID: 15556835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate intake and risk of Parkinson's disease.
    Chen H; Zhang SM; Schwarzschild MA; Hernán MA; Logroscino G; Willett WC; Ascherio A
    Am J Epidemiol; 2004 Aug; 160(4):368-75. PubMed ID: 15286022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.
    Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM
    Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homocysteine is not associated with global motor or cognitive measures in nondemented older Parkinson's disease patients.
    Camicioli RM; Bouchard TP; Somerville MJ
    Mov Disord; 2009 Jan; 24(2):176-82. PubMed ID: 18951534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations.
    O'Suilleabhain PE; Sung V; Hernandez C; Lacritz L; Dewey RB; Bottiglieri T; Diaz-Arrastia R
    Arch Neurol; 2004 Jun; 61(6):865-8. PubMed ID: 15210523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma cysteine and sulphate levels in patients with motor neurone, Parkinson's and Alzheimer's disease.
    Heafield MT; Fearn S; Steventon GB; Waring RH; Williams AC; Sturman SG
    Neurosci Lett; 1990 Mar; 110(1-2):216-20. PubMed ID: 2325885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical course in Parkinson's disease with elevated homocysteine.
    O'Suilleabhain PE; Oberle R; Bartis C; Dewey RB; Bottiglieri T; Diaz-Arrastia R
    Parkinsonism Relat Disord; 2006 Mar; 12(2):103-7. PubMed ID: 16368256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial function markers in parkinsonian patients with hyperhomocysteinemia.
    Bostantjopoulou S; Katsarou Z; Frangia T; Hatzizisi O; Papazisis K; Kyriazis G; Kiosseoglou G; Kazis A
    J Clin Neurosci; 2005 Aug; 12(6):669-72. PubMed ID: 16040247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.